Skip to content

Ketamine for severe depression

Antidepressant effects of Ketamine and ECT: A Pilot Comparison

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021184
Enrollment
60
Registered
2019-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F315- Bipolar disorder, current episodedepressed, severe, with psychotic features Health Condition 2: F314- Bipolar disorder, current episodedepressed, severe, without psychotic features Health Condition 3: F332- Major depressive disorder, recurrent severe without psychotic features Health Condition 4: F333- Major depressive disorder, recurrent, severe with psychotic symptoms Health Condition 5: F323- Major depressive disorder, singleepisode, severe with psychotic features He

Interventions

Intervention1: Ketamine Hydrochloride: I.V. Ketamine hydrochloride (0.5 mg/kg over 45 min) will be administered by I.V. infusion with the use of syringe pump and will be observed for side effects if a
succinylcholine (0.5-1mg/kg) will be administered as a muscle relaxant after the induction of anesthesia. The stimulus intensity will be determined by a dose titration procedure (starting at 60 mC) an

Sponsors

National Institute of Mental Health and Neurosciences Bengaluru
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Both unipolar and bipolar depression of age 18 to 65 who meet ICD-10 criteria for severe depression (with or without psychotic symptoms) is to be taken in study

Exclusion criteria

Exclusion criteria: Patients who have other diagnosed co-morbid psychiatric illness, other diagnosed chronic medical or neurological illness, fulfill criteria for substance dependence according to ICD-10 (Except nicotine) in past one month, Pregnant and post-partum female

Design outcomes

Primary

MeasureTime frame
To assess and compare antidepressant effects of ECT and Ketamine in severe depressive disorder patients (with or without psychotic symptoms)Timepoint: 15 days

Secondary

MeasureTime frame
To assess and compare cognitive deterioration by ECT and ketamine in severe depressive disorder patients (with or without psychotic symptoms)Timepoint: 15 days

Countries

India

Contacts

Public ContactDr Ravi Kumar Sharma

National Institute of Mental health and Neurosciences (NIMHANS), Bangalore-560029

cnkumar1974@gmail.com080-26995254

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 26, 2026